MedTrace Logo

Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese Patients

NCT04560452 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1018

Last updated 2025-10-08

No results posted yet for this study

Summary

This is a multi-centre, prospective, non-interventional study. The study will enrol about 860 Chinese cancer patients from around 56 sites. For OC cohort, the subjects who had received olaparib for at least one dose before study enrolment in real world practices will be enrolled ( n=800) . For PC cohort, according to the doctor's decision, patients who have prescribed and agreed to start taking at least one dose of Olaparib will be enrolled ( n=60). Patient's treating physician is in charge of prescribing (including dose-adjusting or interruption) or discontinuation of olaparib.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Zhongqiu Lin · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-15
Primary Completion
2025-09-05
Completion
2025-09-05

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04560452 on ClinicalTrials.gov